Cullinan Therapeutics
CGEM · NASDAQ
$14.83+$0.85 (+6.08%)TodayMarket closed ·
Prev close $13.98
EPS: actual vs estimate
Beat the estimate in 7 of the last 8 quarters, by 10.3% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.826 | -$0.81 | +1.9% |
| Q1 FY26 | -$0.8453 | -$0.75 | +11.3% |
| Q4 FY25 | -$0.8256 | -$0.77 | +6.7% |
| Q3 FY25 | -$0.9764 | -$0.77 | +21.1% |
| Q2 FY25 | -$0.8497 | -$1.07 | −25.9% |
| Q1 FY25 | -$0.8173 | -$0.74 | +9.5% |
| Q4 FY24 | -$0.7729 | -$0.73 | +5.6% |
| Q3 FY24 | -$0.8221 | -$0.69 | +16.1% |
Earnings calls
- Shareholder/Analyst Call - Cullinan Therapeutics, Inc.
- Special Call - Cullinan Therapeutics, Inc.
- Citi’s 2026 Virtual Oncology Leadership Summit
- Special Call - Cullinan Therapeutics, Inc.
- Morgan Stanley 23rd Annual Global Healthcare Conference
- Special Call - Cullinan Therapeutics, Inc.
- Shareholder/Analyst Call - Cullinan Therapeutics, Inc.
- Morgan Stanley 22nd Annual Global Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.